Chronic obstructive pulmonary disease patient journey: Hospitalizations as window of opportunity for extra-pulmonary intervention

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 16, Issue 3, 2013, Pages 278-283

  Lainscak, Mitja ^a,b   Gosker, Harry R ^c   Schols, Annemie M W J ^c  

^a University Clinic of Pulmonary and Allergic Diseases Golnik   (Slovenia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

body composition; chronic obstructive pulmonary disease; exercise; hospitalization; nutrition; skeletal muscle

Indexed keywords

ASCORBIC ACID; CANDESARTAN; GLUCOCORTICOID; INSULIN; IRBESARTAN; PLACEBO; PROBIOTIC AGENT; SELENIUM; ZINC;

BODY MASS; CALORIC INTAKE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DIET THERAPY; DISEASE EXACERBATION; DRUG MEGADOSE; FAT MASS; FOOD INTAKE; HEART FAILURE; HOSPITALIZATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LOW DRUG DOSE; NONHUMAN; NUTRITIONAL SUPPORT; PHYSIOTHERAPY; PROTEIN INTAKE; REVIEW;

ANABOLIC AGENTS; BODY COMPOSITION; EXERCISE; HOSPITALIZATION; HUMANS; INFLAMMATION; LUNG; MALNUTRITION; NUTRITIONAL SUPPORT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876411441     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328360285d     Document Type: Review

References (57)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379:1341-1351.
2. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67:957-963.
3. Perera PN, Armstrong EP, Sherrill DL, Skrepnek GH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD 2012; 9:131-141.
4. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbations in chronic obstructive pulmoanry disease. N Engl J Med 2010; 363:1128-1138.
5. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009; 374:744-755.
6. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008; 133:756-766.
7. van de Bool C, Steiner MC. Schools AMWJ. Nutritinal targets to enhance exercise performance in chronic obstructive pulmonary disease. Curr Opin Clin Nutr Metab Care 2012; 15:553-560.
8. Laveneziana P. Palange P on behalf of the ERS Research Seminar Faculty. Physical inactivity, nutritional status and systemic inflammation in COPD. Eur Respir J 2012; 40:522-529.
9. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12:CD000998.
10. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. Am J Respir Crit Care Med 2006; 173:1390-1413.
11. Turan N, Kalko S, Stincone A, et al. A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic bstruc-tive pulmonary disease. PloS Comput Biol 2011; 7:e1002129.
12. van den Borst B, Slot IG, Hellwig VA, et al. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol 2012. doi: 10.1152/japplphysiol.00508.2012.
13. Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol 2012. doi: 10.1152/japplphysiol.00790.2012.
14. Doehner W, von Haehling S, Anker SD, Lainscak M. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr 2009; 121:293-296.
15. Natanek SA, Gosker HR, Slot IG, et al. Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD. Eur Respir J2012 [Epub ahead of print]. doi: 10.1183/09031936.00098412.
16. Doehner W, Haeusler KG, Endres M, et al. Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. Respir Med 2011; 105 (Suppl 1):S12-S19.
17. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PloS One 2012; 7:e37483.
18. van den Borst B, Gosker HR, Schols AM. Central fat and peripheral muscle: partners in crime in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:8-13.
19. van den Borst B, Gosker HR, Koster A, et al. The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr 2012; 96:516-526.
20. Rutten EP, Breyer MK, Spruit MA, et al. Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease. Clin Nutr 2010; 29:756-760.
21. Langen RC, Haegens A, Vernooy JH, et al. NF-kb activation is required for the transition of pulmonary inflammation to muscle atrophy. Am J Respir Cell Mol Biol 2012; 47:288-297.
22. Hommelberg PP, Langen RC, Schols AM, et al. Inflammatory signaling in skeletal muscle insulin resistance: green signal for nutritional intervention? Curr Opin Clin Nutr Metab Care 2010; 13:647-655.
23. Remels AH, Schrauwen P, Broekhuizen R, et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007; 30:245-252.
24. Andreas S, Herrmann-Lingen C, Raupach T, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006; 27:972-979.
25. Pocock SJ, McMurray JJ, Dobson J, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assess-men tof reduction inmortality and morbidity (CHARM) programme. Eur Heart J 2008; 29:2641-2650.
26. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057.
27. Doehner W, Todorovic J, Kennecke C, et al. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. Int J Cardiol 2012; 161:137-142.
28. Lainscak M, Andreas S, Scanlon PD, et al. Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med 2006; 45:837.
29. Schols AMWJ, Gosker HR. The patophysiology of cachexia in chronic obstru-citve pulmonary disease. Curr Opin Support Palliat Care 2009; 3:282-287.
30. Collins PF, Stratton RJ, Elia M. Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Clin Nutr 2012; 95:1385-1395.
31. Vermeeren MAP, Schols AMWJ, Wouters EFM. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Eur Respir J 1997; 10:2264-2269.
32. Raguso CA, Luthy C. Nutritional status in chronic obstructive pulmonary disease: role of hypoxia. Nutrition 2011; 27:138-143.
33. Vermeeren MA, Wouters EF, Geraerts-Keeris AJ, Schols AM. Nutritional support in patients with chronic obstructive pulmoanry disease during hospi-talisation for an acute exacerbation: a randomized controlled feasibility trial. Clin Nutr 2004; 23:1184-1192.
34. Lainscak M, von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle 2011; 2:81-86.
35. Benedik B, Farkas J, Kosnik M, et al. Mini nutritional assessment, body composition, and hospitalisations in patients with chronic obstructive pul monary disease. Respir Med 2011; 105 (Suppl 1):S38-S43.
36. Hallin R, Gudmundsson G, Suppli Ulrik C, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 2007; 101:1954-1960.
37. Cooper M, Douglas G, Perchonok M. Developing the NASA food system for long-duration missions. J Food Sci 2011; 76:R40-R48.
38. Jeukendrup AE. Nutrition for endurance sports: marathon, triathlon, and road cycling. J Sports Sci 2011; 29 (Suppl 1):S91-S99.
39. Stellingwerff T, Maughan RJ, Burke LM. Nutrition for power sports: middle-distance running, track cycling, rowing, canoeing/kayaking, and swinimg. J Sports Sci 2011; 29 (Suppl 1):S79-S89.
40. van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc 2010; 11:179-187.
41. Herr C, Greulich T, Koczulla RA, et al. The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer. Respir Res 2011; 12:31.
42. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2012; 156:105-114.
43. El-Attar M, Said M, El-Assal G, et al. Serum trace element levels in COPD patient: the relation between trace element supplementation and period of mechanical ventilation in a randomized controlled trial. Respirology 2009; 14:1180-1187.
44. Isbaniah F, Wiyono WH, Yunus F, et al. Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial. J Clin Pharm Ther 2011; 36:568-576.
45. Pison CM, Cano NJ, Cherion C, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomized controlled trial. Thorax 2011; 66:953-960.
46. Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003; 124:1733-1742.
47. Pansters NA, Langen RC, Wouters E, Schols AM. Synergistic stimulation of myogenesis by glucocorticoid and IGF-I signaling. J Appl Physiol 2012. doi: 10.1152/japplphysiol.00503.2012.
48. Dioguardi FS. Clinical use of amino acids as dietary supplement: pros and cons. J Cachexia Sarcopenia Muscle 2011; 2:75-80.
49. Engelen MP, De Castro CL, Rutten EP, et al. Enhanced anabolic response to milk protein sip feeding in elderly subjects with COPD is associated with a reduced splanchnic extraction of multiple amino acids. Clin Nutr 2012;31:616-624.
50. Engelen MP, Rutten EP, De Castro CL, et al. Casein protein results in higher prandial and exercise induced whole body protein anabolism than whey protein in Chronic Obstructive Pulmonary Disease. Metabolism 2012;61:1289-1300.
51. Tang CY, Blackstock FC, Clarence M, Taylor NF. Early rehabilitation exercise program for inpatients during an acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial. J Cardiopulm Rehabil Prev 2012; 32:163-169.
52. Babu AS, Noone MS, Haneef M, Samuel P. The effects of 'on-call/out of hours' physical therapy in acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Clin Rehabil 2010; 24:802-809.
53. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease.Am JRespir Crit Care Med 2010; 181:1072-1077.
54. Meglic U, Sorli J, Kosnik M, Lainscak M. Feasibility of transcutaneous electrical muscle stimulation in acute exacerbation of COPD. Wien Klin Wochenschr 2011; 123:384-387.
55. Giavedoni S, Deans A, McCaughey P, et al. Neuromuscular electrical stimula tion prevents muscle function deterioration in exacerbated COPD: a pilot study. Respir Med 2012; 106:1429-1436.
56. Abdellaoui A, Prefault C, Gouzi F, et al. Skeletal muscle effects of electro-stimulation after COPD exacerbation: a pilot study. Eur Respir J 2011;38:781-788.
57. Kosmas EN, Dumitru S, Kougianos K, et al. Assessment of public awareness on chronic obstructive pulmonary disease in Athens, Greece, and the effects of an awareness-raising national actin plan. J Public Health Epidemiol 2011;3:433-439.